Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

from the RADIANT-3 study will be submitted for presentation at the European Society for Medical Oncology annual meeting taking place in Milan, Italy in October. Additionally, worldwide regulatory filings are planned for 2010.

Study details

RADIANT-3 is a Phase III prospective, double-blind, randomized, parallel group, placebo-controlled, multicenter study. The trial examined the efficacy and safety of everolimus plus best supportive care versus placebo plus best supportive care in 410 patients with advanced pancreatic NET, also known as islet cell tumors. Patients who met the study's entry criteria were randomized 1:1 to receive either daily everolimus (10 mg) or daily placebo orally.

The primary endpoint of RADIANT-3 is progression-free survival. Secondary endpoints include safety, objective response rate and overall survival.

About neuroendocrine tumors

Neuroendocrine tumors arise from cells that can produce and secrete a variety of hormones that regulate bodily functions. There are many types of NET that can occur throughout the body; however, most are found in the gastrointestinal tract, pancreas and lungs(3). Because NET are relatively rare, there is no routine screening and patients often experience delays of five to seven years before receiving an accurate diagnosis(3),(4). As a result of this, patients with NET often have advanced disease when diagnosed(3). Although considered a rare cancer, the incidence of NET is increasing dramatically, having quadrupled in the past 30 years(3).

About everolimus

In the US, everolimus is approved under the trade name Afinitor® (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 RadiologyAuction will have their first auction starting ... demonstrations at the end of the auction on May ... and Fuji Cr,s, Agfa and Sony, printers and GE ... Various imaging equipment will be available at later auctions ... years of buying and selling imaging equipment, the brokers ...
(Date:5/4/2015)...  Oncobiologics, Inc., a biotherapeutics company focused on ... completed the construction of its GMP commercial launch ... Cranbury, New Jersey . The ... to utilize multiple technologies that enable rapid deployment ... use of the latest single-use technologies, the facility ...
(Date:5/4/2015)... Calif. , May 4, 2015  Isis Pharmaceuticals, ... exclusive license agreement with Bayer HealthCare (Bayer) to develop ... thrombosis. Under the terms of the agreement, Isis is ... payments, including an immediate $100 million up-front payment and ... following a Phase 2 study in patients with compromised ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... -- Clinilabs, an early phase and specialty CRO that ... today announced that they have opened a second Phase ... 15,000 square foot Specialty Pharma Phase I Unit features ... bioanalytic laboratory, pharmacy, and exam rooms. Since ...
... Inc. (NASDAQ: GNVC ) announced today that on ... of its common stock to Cynthia Collins, its newly appointed ... by the Compensation Committee of GenVec,s Board of Directors and ... material to Ms. Collins,s acceptance of employment with GenVec in ...
Cached Medicine Technology:Clinilabs Opens Phase I Unit In Eatontown, New Jersey 2GenVec Reports Inducement Award 2
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... 2015 The opportunity for children to dream ... the motivating forces behind The Fairy Godmother Next Door, a ... Amy L. Stark. , The inspiration for the enchanting story ... comes from Stark’s desire to be a fairy godmother. , ... godmother to my neighbors’ children since they were born. We ...
(Date:5/4/2015)... 2015 The U.S. healthcare worker shortage ... the ranks of senior citizens (1) and 27 million ... over-burdened healthcare system. Additionally, as older healthcare employees retire, ... Per the U.S. Census Bureau, the number of American ... by 2050 while those 25 to 54 will likely ...
(Date:5/4/2015)... and Seattle, WA (PRWEB) May 04, 2015 ... formation of a collaboration to facilitate development of NM108, ... ophthalmic disorders that lead to blindness, including Diabetic Retinopathy. ... MiDROPS™ formulation platform developed by EyeCRO, which can deliver ... via a topical eyedrop. , Under the terms ...
(Date:5/4/2015)... New findings released today from a ... show that people diagnosed with a brain tumor needed ... clinical trials, at the time of diagnosis, and had ... about their course of treatment. The release of these ... brain tumor volunteer network, the ABTA CommYOUnity™, dedicated to ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... HealthDay Reporter , TUESDAY, March 6 (HealthDay News) ... disorders, especially post-traumatic stress disorder, are more likely than ... new study finds. Use of these opioid pain ... addictive and cause more serious problems, researchers say. ...
... Most stroke patients undergo both CT and MRI brain scans, ... stroke care in the United States, a new study indicates. ... 600,000 patients diagnosed with stroke between 1999 and 2008 in ... who had MRI scans also had CT brain scans. ...
... 6 (HealthDay News) -- When it comes to wine, a new ... lost on many consumers. The professionals seem to have a ... Penn State University explained. As a result, wine experts are able ... other people just can,t taste. "What we found is that ...
... of evading the drugs used by oncologists to try and eliminate ... , Now, researchers at UCLA,s Jonsson ... gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene. ... that encodes proteins, called the exome, Jonsson Cancer Center scientists discovered ...
... 2012) Researchers at Moffitt Cancer Center and colleagues from ... Kingdom have used two genome-wide association studies (GWAS) one ... detect a novel set of genes found to be associated ... the door to new therapies for treating epithelial ovarian cancer ...
... research from Carnegie Mellon University,s Marcel Just provides an ... and communication disorders to restricted interests and gives ... Autism has long been a scientific enigma, mainly ... now. Published in the journal Neuroscience and ...
Cached Medicine News:Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 2Health News:Narcotic Painkillers Another Threat to Traumatized War Vets: Study 3Health News:Brain Scans Overused on U.S. Stroke Patients, Study Says 2Health News:Wine Ratings May Be Meaningless for Most People 2Health News:UCLA scientists uncover mechanism for melanoma drug resistance 2Health News:UCLA scientists uncover mechanism for melanoma drug resistance 3Health News:Researchers find possible genetic keys to surviving epithelial ovarian cancer 2Health News:New brain imaging and computer modeling predicts autistic brain activity and behavior 2Health News:New brain imaging and computer modeling predicts autistic brain activity and behavior 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: